Abstract
BACKGROUND: Screening for colorectal cancer improves cancer-specific survival (CSS) through the detection of early-stage disease; however, its impact on overall survival (OS) is unclear. The present study examined tumour and host determinants of outcome in TNM Stage I disease.
METHODS: All patients with pathologically confirmed TNM Stage I disease across 4 hospitals in the North of Glasgow between 2000 and 2008 were included. The preoperative modified Glasgow Prognostic Score (mGPS) was used as a marker of the host systemic inflammatory response (SIR).
RESULTS: There were 191 patients identified, 105 (55 %) were males, 91 (48 %) were over the age of 75 years and 7 (4 %) patients underwent an emergency operation. In those with a preoperative CRP result (n = 150), 35 (24 %) patients had evidence of an elevated mGPS. Median follow-up of survivors was 116 months (minimum 72 months) during which 88 (46 %) patients died; 7 (8 %) had postoperative deaths, 15 (17 %) had cancer-related deaths and 66 (75 %) had non-cancer-related deaths. 5-year CSS was 95 % and OS was 76 %. On univariate analysis, advancing age (p < 0.001), emergency presentation (p = 0.008), and an elevated mGPS (p = 0.012) were associated with reduced OS. On multivariate analysis, only age (HR = 3.611, 95 % CI 2.049-6.365, p < 0.001) and the presence of an elevated mGPS (HR = 2.173, 95 % CI 1.204-3.921, p = 0.010) retained significance.
CONCLUSIONS: In patients undergoing resection for TNM Stage I colorectal cancer, an elevated mGPS was an objective independent marker of poorer OS. These patients may benefit from a targeted intervention.
Original language | English |
---|---|
Pages (from-to) | 1485-91 |
Number of pages | 7 |
Journal | World Journal of Surgery |
Volume | 40 |
Issue number | 6 |
DOIs | |
Publication status | Published - Jun 2016 |
Externally published | Yes |
Keywords
- Age Factors
- Aged
- C-Reactive Protein/metabolism
- Colorectal Neoplasms/pathology
- Emergencies
- Female
- Follow-Up Studies
- Humans
- Male
- Neoplasm Staging
- Prognosis
- Survival Rate
- Systemic Inflammatory Response Syndrome/blood
- Time Factors
- Treatment Outcome